HCV immunoassays employing C domain antigens
AssigneeChiron Corporation
InventorsMichael Houghton, Qui-Lim Choo, George Kuo
Life of this patent
Estimating the term…
Abstract
Immunoassays for the detection of antibodies to HCV are provided which employ "C" domain antigens. Immunoassay kits comprising such antigens are also provided.
Claims41
An immunoassay for detecting antibodies that bind to a hepatitis C virus (HCV) polypeptide comprising:
- (a) providing an antigen comprising the C domain polypeptide encoded by HCV cDNA deposited under ATCC No. 40394 or an immunlogically reactive fragment thereof of at least 8 contiguous amino acid residues;
- (b) incubating said antigen with a biological sample under conditions that allow for formation of an antibody-antigen complex;
- and
- (c) detecting any antibody-antigen complexes comprised of said antigen.
An immunoassay for detecting antibodies that bind to an HCV polypeptide comprising:
- (a) providing an antigen comprising a polypeptide selected from the group consisting of (i) a polypeptide consisting of a sequence of amino acid residues 1 to 84, amino acid residues 9 to 177, or amino acid residues 1 to 120 of FIG. 90 and (ii) immunlogically reactive fragments of polypeptide (i) of at least 8 contiguous amino acid residues;
- (b) incubating said antigen with a biological sample under conditions that allow for formation of an antibody-antigen complex;
- and
- (c) detecting any antibody-antigen complex comprised of said antigen.
A kit for an immunoassay for detecting antibodies that bind to a hepatitis C virus (HCV) polypeptide comprising an antigen in a suitable container, wherein the antigen is comprised of the C domain polypeptide encoded by HCV cDNA deposited under ATCC No. 40394 or an immunologically reactive fragment thereof of at least 8 contiguous amino acid residues and wherein the antigen is attached to a solid support.
A kit for an immunoassay for detecting antibodies that bind to a hepatitis C virus (HCV) polypeptide comprising an antigen in a suitable container, wherein the antigen is comprised of a polypeptide selected from the group consisting of (i) a polypeptide consisting of a sequence of amino acid residues 1 to 84 and amino acid residues 9 to 177 of FIG. 90 and (ii) an immunologically reactive fragment of polypeptide (i) of at least 8 contiguous amino acid residues and wherein the antigen is attached to a solid support.
Dependencies are inferred from the claim text.